Sleep promoters and insomnia;Hipnoindutores e insônia

Revista Brasileira de Psiquiatria

Volumn 27, Issue SUPPL. 1, 2005, Pages

  Poyares, Dalva ^a,d   Pinto Jr , Luciano Ribeiro ^a   Tavares, Stella ^b   Barros Vieira, Sergio ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HÔPITAL SAINT ANTOINE   (France)

^d NONE   (Brazil)

Author keywords

Antipsychotic agents; Benzodiazepines; Hypnotics and sedatives; Melatonin; Pyridines; Sleep initiation and maintenance disorders

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; DOXEPIN; HYPNOTIC AGENT; IMIDAZOPYRIDINE DERIVATIVE; MELATONIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PYRIDINE DERIVATIVE; SEDATIVE AGENT; TRAZODONE; VALERIAN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CHRONIC DISEASE; CLINICAL FEATURE; DEMOGRAPHY; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG USE; HUMAN; INSOMNIA; LONG TERM CARE; MENTAL PATIENT; PRESCRIPTION; REVIEW; SEDATION; SLEEP; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 19044395525     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Poyares D, Tufik S, Barros-Vieira S, Hora F, Minhoto G, Pinto LR, et al. I Consenso Brasileiro de Insônia, Sociedade Brasileira do Sono e Federação Latino Americana das Sociedades de Sono. Hypnos; 2003;4(Supl 2).
2. American Psychiatry Association. Benzodiazepine dependence, toxicity and abuse: a task force report of the American Psychiatry Association. Washington, (DC): American Psychiatry Association; 1990.
3. Higgins K, Cooper-Stanbury M, Williams P. Statistics on drug use in Australia 1998. Canberra: Australian Institute of Health and Welfare; 2000.
4. Centro Brasileiro de Informações sobre Drogas Psicotrópicas. Departamento de Psicobiologia, UNIFESP, São Paulo-Brasil. Boletim. 2003;47(11):4.
5. th European Congress on Sleep Research. Brussels, Belgium, 16-21 June 1996].
6. Mari JJ, Almeida-Filho N, Coutinho E, Andreoli SB, Miranda CT, Streiner D. The epidemiology of psychotropic use in the city of São Paulo. Psychol Med. 1993;23(2):467-74.
7. Dunbar GC, Perera MH, Jenner FA. Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry. 1989;155:836-41.
8. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep. 1997;20(9):715-23.
9. Luderer HJ, Schulz M, Mayer M. Long-term administration of benzodiazepines - disease follow-up, sequelae, treatment. A retrospective clinical record evaluation of 194 patients. Psychiatr Prax. 1995;22(6):231-4.
10. Mant A, de Burgh S, Mattick RP, Donnelly N, Hall W. Insomnia in general practice. Results from NSW General Practice Survey 1991-1992. Aust Fam Physician. 1996;(Suppl 1):S15-8.
11. Ohayon MM, Roth T. What are the contributing factors for insomnia in the general population? J Psychosom Res. 2001;51(6):745-55.
12. Ohayon MM, Zulley J, Guilleminault C, Smirne S, Priest RG. How age and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc. 2001;49(4):360-6.
13. De Lima MS, Hotopf M, Mari JJ, Beria JU, De Bastos AB, Mann A. Psychiatric disorder and the use of benzodiazepines: an example of the inverse care law from Brazil. Soc Psychiatry Psychiatr Epidemiol. 1999;34(6):316-22.
14. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14(5):287-303.
15. Poyares D, Guilleminault C, Ohayon MM, Tufik S. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res. 2004;38(3):327-34.
16. Schneider-Helmert D. Why low dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand. 1988;78(6):706-11.
17. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription of hypnotics. Biol Psychiatry. 1998;43(9):687-93.
18. Barter G, Cormack M. The long-term use of benzodiazepines: patients' views, accounts and experiences. Fam Pract. 1996;13(6):491-7.
19. Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol. 1985;4(3):189-94.
20. Gaillard JM, Blois R. Sleep pharmacology of typical and atypical ligands of benzodiazepine receptors. Pharmacol Biochem Behav. 1988;29(4):799-801.
21. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000;60(2):413-45.
22. Mitler MM. Non selective and selective benzodiazepine receptor agonists: where are we today? Sleep. 2000;23(Suppl 1):S39-47.
23. Besset A, Tafti M, Villemin E, Borderies P, Billiard M. Effects of zolpidem on the architecture and cyclical structure of sleep in poor sleepers. Drugs Exp Clin Res. 1995;21(4):161-9.
24. Colle M, Rosenzweig P, Bianchetti G, Fuseau E, Ruffie A, Ruedas E, et al. Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: a double-blind study in young adults and children. Horm Res. 1991;35(1):30-4.
25. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: the MoVIES project. J Am Geriatr Soc. 1996;44(7):778-84.
26. Hohagen F, Rink K, Kappler C, Schramm E, Riemann D, Weyerer S, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci. 1993;242(6):329-36.
27. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med. 1998;158(10):1099-107.
28. Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf. 1993;9(2):93-103.
29. Hohagen F, Kappler C, Schramm E, Riemann D, Weterer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1995;17(6):551-4.
30. Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res. 1998;26(1):13-24.
31. Hajak G, Cluydts R, Allain H, Estivill E, Parrino L, Terzano MG, et al. The challenge of chronic insomnia: is non-nightly hypnotic treatment a feasible alternative? Eur Psychiatry. 2003;18(5):201-8. Review.
32. Hajak G, Geisler P. Experience with zolpidem 'as needed' in primary care settings. CNS Drugs. 2004;18(Suppl 1):35-40. Discussion 41, 43-5. Review.
33. Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004;65(8):1128-37.
34. Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(3):421-31.
35. Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol. 1998;51(3):273-83.
36. Sakulsripong M, Curran HV, Lader M. Does tolerance develop to the sedative and amnestic effects of antidepressants? A comparison of amitryptiline, trazodone and placebo. Eur J Clin Pharmacol. 1991;40(1):43-8.
37. a ed. São Paulo: Lemos; 2001. p. 115-39.
38. Krystal AD. The changing perspective on chronic insomnia management. J Clin Psychiatry. 2004;65(Suppl 8):20-5.
39. Marden S. Antipsychotic medication. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology. Washington, DC: American Psychitrix Publishing; 1998. p. 111-24.
40. Owens MJ, Risch SC. Atypical AP. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology. Washington, DC: American Psychitrix Publishing; 1998. p. 125-54.
41. th ed. New York: Mc Graw-Hill; 2001. p. 485-520.
42. Wiegand MH. Drug treatment of sleep disorders in the elderly. Internist (Berl). 2003;44(9):1187-92.
43. Wortelboer U, Cohrs S, Rodenbeck A, Ruther E. Tolerability of hypnosedatives in older patients. Drugs Aging. 2002;19(7):529-39.
44. Estivill E, de la Fuente V, Segarra F, Albares J. [The use of olanzapine in sleep disorders. An open trial with nine patients]. Rev Neurol. 2004;38(9):829-31. Spanish.
45. Adler L. [Drugs for the treatment of sleep disturbances-neuroleptics and antidepressants]. Z Arztl Fortbild Qualitatssich. 2001;95(1):27-31. German.
46. Santos MS, Ferreira F, Cunha AP, Carvalho AP, Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med. 1994;60(3):278-9.
47. Santos MS, Ferreira F, Cunha AP, Carvalho AP, Ribeiro CF, Macedo T. Synaptosomal GABA release as influenced by valerian root extract - involvement of the GABA carrier. Arch Int Pharmacodyn Ther. 1994;327(4):220-31.
48. Balderer G, Borbély AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985;87(4):406-9.
49. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. 1994;27(4):146-51.
50. Poyares DR, Guilleminault C, Ohayon MM, Tufik S. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):539-45.
51. Seabra MLV, Bignotto M, Pinto Jr LR, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29(4):193-200.
52. Arendt J. Melatonin and the mammalian pineal gland. London: Chapman & Hall; 1995.
53. Cagnacci A, Elliot JA, Yen SSC. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab. 1992;75(2):447-52.
54. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch AJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994;91(5):1824-8.
55. Zaidan R, Geoffriau M, Brun J, Taillard J, Bureau C, Chazot G, et al. Melatonin is able to influence its secretion in humans: description of a phase-response curve. Neuroendocrinology. 1994;60(1):105-12.
56. Arendt J, Deacon S. Treatment of circadian rhythm disorders-melatonin. Chronobiol Int. 1997;14(2):185-204.
57. Boivin DB, James FO. Insomnia due to circadian rhytm disturbances. In: Szuba MP, Kloss JD, Dinges DF, editors. Insomnia: principles and management. Cambridge: Cambridge University Press; 2003. p. 96-114.
58. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). 1990;100(2):222-6.
59. Reid K, Van den Heuvel C, Dawson D. Day-time melatonin administration: effects on core temperature and sleep onset latency. J Sleep Res. 1996;5(3):150-4.
60. Pires MLN, Benedito-Silva AA, Pinto L, Souza L, Calil HM. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res. 2001;31(4):326-32.
61. Tzischinsky O, Shlitner A, Lavie P. The association between nocturnal sleep gates and nocturnal onset of urinary 6-sulfatoxymelatonin. J Biol Rhythms. 1993;8(3):199-209.
62. Zhdanova IV, Wurtman RJ, Lynch HL, Ives JR, Dollins AB, Morabito C, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57(5):552-8.
63. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin given 2-4 hours before habitual bedtime on sleep in normal young humans. Sleep. 1996;19(5):423-31.
64. Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol. 1995;275(2):213-6.
65. Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl). 1996;126(2):179-81.
66. Pinto LR Jr, Seabra ML, Tufik S. Different criteria of sleep latency and the effect of melatonin on sleep consolidation. Sleep. 2004;27(6):1089-92.
67. Brusco LI, Fainstein I, Marquez M, Cardinali DP. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept. 1999;8(1-2):126-31.
68. Fainstein I, Bonetto AJ, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res. 1997;58:990-1000.
69. Woodward M. Insomnia in the elderly. Aust Fam Physician. 1999;28(7):653-8.
70. Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep. 2004;27(7):1319-25.
71. Panzer A, Viljoen M. The validity of melatonin as oncostatic agent. J Pineal Res. 1997;22(4):184-202.
72. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin J, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36(1):1-9.
73. Nelson RJ, Demas GE, Klein SL, Kriegsfeld LS. The influence of season, photoperiod, and pineal melatonin on immune function. J Pineal Res. 1995;19(4):149-65.
74. Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless leg syndrome: relationship with biological markers. Ann Neurol. 2004;55(3):372-80.
75. Cohen AS, Kraube H. Rare nocturnal headaches. Curr Opin Neurol. 2004;17(3):295-9.
76. Spence DW, Kayumov L, Chen A, Lowe A, Jain U, Katzman MA, et al. Acupuncture increases nocturnal melatonin secretion and reduces insomnia and anxiety: a preliminary report. J Neuropsychiatry Clin Neurosci. 2004;16(1):19-28.
77. Harinath K, Malhotra AS, Pal K, Prasad R, Kumar R, Kain TC, et al. Effects of Hatha yoga and Omkar meditation on cardiorespiratory performance, psychologic profile, and melatonin secretion. J Altern Complement Med. 2004;10(2):261-8.
78. Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther. 2004;311(2):547-59.
79. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT(1)/MT(2) receptor agonist. Neuropharmacology. 2005;48(2):301-10.
80. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979-91.